Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells

Pancreas

Volumn 41, Issue 3, 2012, Pages 397-408

  Ma, Danjun ^a   Wang, Jiarui ^b   Zhao, Yingchun ^a   Lee, Wai Nang Paul ^c   Xiao, Jing ^a   Go, Vay Liang W ^d   Wang, Qi ^b   Recker, Robert R ^a   Xiao, Gary Guishan ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

MAPK ERK; metabolic inhibitor; pancreas cancer; quantitative proteomics; TNF NF B; turnover rate

Indexed keywords

5 CHLORO 1H INDOLE 2 CARBOXYLIC ACID[1 (4 FUOROBENZYL) 2 (4 HYDROXYPIPERIDIN 1 YL) 2 OXOETHYL]AMIDE; ANTINEOPLASTIC AGENT; CP 320626; GLYCOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DYNAMICS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

AMIDES; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME INHIBITORS; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; HUMANS; INDOLES; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PEPTIDE MAPPING; PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84859103649     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318236f022     Document Type: Article

References (49)

1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029-1033.
2. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330:1340-1344.
3. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-1495. (Pubitemid 17038084)
4. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of lDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997;94:6658-6663. (Pubitemid 27281920)
5. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000;275: 21797-21800. (Pubitemid 30621745)
6. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892-3899. (Pubitemid 38697301)
7. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles'heel. Cancer Cell. 2008;13:472-482. (Pubitemid 351766797)
8. Weinhouse S. Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G.H.A. Clowes Memorial Lecture. Cancer Res. 1972;32:2007-2016.
9. Gatenby RA, Gawlinski ET, Gmitro AF, et al. Acid-mediated tumor invasion: amultidisciplinary study. Cancer Res. 2006;66:5216-5223. (Pubitemid 43844945)
10. Crabtree HG. Observations onthe carbohydrate metabolism of tumours. Biochem J. 1929;23:536-545.
11. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
12. Rais B, Comin B, Puigjaner J, et al. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett. 1999;456:113-118. (Pubitemid 29339052)
13. Mandal S, Freije WA, Guptan P, et al. Metabolic control of g1-S transition: cyclin E degradation by p53-induced activation of the ubiquitin-proteasome system. J Cell Biol. 2010;188:473-479.
14. Somsak L, Czifrak K, Toth M, et al. New inhibitors of glycogen phosphorylase as potential antidiabetic agents. Curr Med Chem. 2008;15:2933-2983.
15. Oikonomakos NG. Glycogen phosphorylase as amolecular target for type 2 diabetes therapy. Curr Protein Pept Sci. 2002;3:561-586. (Pubitemid 35331543)
16. Lee WN, Guo P, Lim S, et al. Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. Br J Cancer. 2004;91:2094-2100. (Pubitemid 40128777)
17. Zhang H, Cao R, Lee WN, et al. Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways. J Proteome Res. 2010;9:980-989.
18. Zhao Y, Lee WN, Lim S, et al. Quantitative proteomics: measuring protein synthesis using 15N amino acid labeling in pancreatic cancer cells. Anal Chem. 2009;81:764-771.
19. Xiao GG, Nel AE, Loo JA. Nitrotyrosine-modified proteins and oxidative stress induced by diesel exhaust particles. Electrophoresis. 2005;26:280-292. (Pubitemid 40202145)
20. Xiao GG, Wang M, Li N, et al. Use of proteomics to demonstrate a hierarchical oxidative stress response to diesel exhaust particle chemicals in a macrophage cell line. J Biol Chem. 2003;278:50781-50790. (Pubitemid 37548927)
21. Jiang XS, Tang LY, Cao XJ, et al. Two-dimensional gel electrophoresis maps of the proteome and phosphoproteome of primitively cultured rat mesangial cells. Electrophoresis. 2005;26:4540-4562.
22. Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate. 1988;12:99-110.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63. (Pubitemid 14203433)
24. Xiao GG, Garg M, Lim S, et al. Determination of protein synthesis in vivo using labeling from deuterated water and analysis of MALDI-TOF spectrum. J Appl Physiol. 2008;104:828-836. (Pubitemid 351468813)
25. Vizan P, Sanchez-Tena S, Alcarraz-Vizan G, et al. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis. 2009;30:946-952.
26. Toyoshima H, Hunter T. p27, anovel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994;78:67-74. (Pubitemid 24228301)
27. Baldin V, Lukas J, Marcote MJ, et al. Cyclin D1 is anuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7:812-821. (Pubitemid 23163585)
28. Ahmed MM, Alcock RA, Chendil D, et al. Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2. J Biol Chem. 2002;277:2234-2246. (Pubitemid 34968811)
29. Garkavtsev I, Grigorian IA, Ossovskaya VS, et al. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature. 1998;391:295-298. (Pubitemid 28099018)
30. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352:345-347. (Pubitemid 21912356)
31. Doherty MK, Whitehead C, McCormack H, et al. Proteome dynamics incomplex organisms: using stable isotopes to monitor individual protein turnover rates. Proteomics. 2005;5:522-533. (Pubitemid 40262069)
32. Pratt JM, Petty J, Riba-Garcia I, et al. Dynamics of protein turnover, a missing dimension in proteomics. Mol Cell Proteomics. 2002;1:579-591.
33. + thymic selection in humans lacking zap-70 kinase. Cell. 1994;76:947-958.
34. Chan AC, Iwashima M, Turck CW, et al. ZAP-70: a70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 1992;71:649-662.
35. Chan AC, Kadlecek TA, Elder ME, et al. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science. 1994;264:1599-1601. (Pubitemid 24227717)
36. Toyabe S, Watanabe A, Harada W, et al. Specific immunoglobulin Eresponses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling. Immunology. 2001;103:164-171. (Pubitemid 32521345)
37. Eyers CE, McNeill H, Knebel A, et al. The phosphorylation of capZ-interacting protein (CapZIP) by stress-activated protein kinases triggers its dissociation from CapZ. Biochem J. 2005;389:127-135. (Pubitemid 40978015)
38. Kellner R, Lichtenfels R, Atkins D, et al. Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics. 2002;2:1743-1751. (Pubitemid 36015510)
39. Mueller HW, Michel A, Heckel D, et al. Identification of an amplified gene cluster in glioma including two novel amplified genes isolated by exon trapping. Hum Genet. 1997;101:190-197. (Pubitemid 28014730)
40. Ou K, Yu K, Kesuma D, et al. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping. J Proteome Res. 2008;7:1518-1528.
41. Montpetit A, Boily G, Sinnett D. A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus. Eur J Hum Genet. 2002;10:62-71. (Pubitemid 34229052)
42. Mayya V, Lundgren DH, Hwang SI, et al. Quantitative phosphoproteomic analysis of t cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal. 2009;2:ra46.
43. Montpetit A, Larose J, Boily G, et al. Mutational and expression analysis of the chromosome 12p candidate tumor suppressor genes in pre-B acute lymphoblastic leukemia. Leukemia. 2004;18:1499-1504. (Pubitemid 39264072)
44. Li AL, Li HY, Jin BF, et al. A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem. 2004;279:49251-49258.
45. Taylor CA, Senchyna M, Flanagan J, et al. Role of eIF5A in TNF-alpha-mediated apoptosis of lamina cribrosa cells. Invest Ophthalmol Vis Sci. 2004;45:3568-3576. (Pubitemid 39298575)
46. Cracchiolo BM, Heller DS, Clement PM, et al. Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva. Gynecol Oncol. 2004;94:217-222. (Pubitemid 38950524)
47. Paul Lee WN, Wahjudi PN, Xu J, et al. Tracer-based metabolomics: concepts and practices. Clin Biochem. 43:1269-1277.
48. Bouvet M, Bold RJ, Lee J, et al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [see comments]. Ann Surg Oncol. 1998;5:681-688. (Pubitemid 28565718)
49. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, et al. Energy metabolism intumor cells. FEBS J. 2007;274:1393-1418.